BRPI0407835A - composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis - Google Patents

composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis

Info

Publication number
BRPI0407835A
BRPI0407835A BRPI0407835-7A BRPI0407835A BRPI0407835A BR PI0407835 A BRPI0407835 A BR PI0407835A BR PI0407835 A BRPI0407835 A BR PI0407835A BR PI0407835 A BRPI0407835 A BR PI0407835A
Authority
BR
Brazil
Prior art keywords
compound
sub
prodrug
pharmaceutically acceptable
vivo
Prior art date
Application number
BRPI0407835-7A
Other languages
English (en)
Inventor
Michael Barry Gravestock
Neil James Hales
Daniel Robert Carcanague
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0304723A external-priority patent/GB0304723D0/en
Priority claimed from GB0318607A external-priority patent/GB0318607D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0407835A publication Critical patent/BRPI0407835A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, éSTER HIDROLISáVEL IN VIVO, MéTODO PARA PRODUZIR UM EFEITO ANTIBACTERIANO EM UM ANIMAL DE SANGUE QUENTE, USO DE UM COMPOSTO OU UM SEU SAL, SOLVATO, PRó-DROGA OU éSTER HIDROLISáVEL IN VIVO FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO OU SEUS SAIS, SOLVATOS, PRó-DROGAS OU éSTERES HIDROLISáVEIS IN VIVO FARMACEUTICAMENTE ACEITáVEIS". São descritos compostos de fórmula (I) ou um seu sal ou um éster hidrolisável in vivo farmaceuticamente aceitável, R1 a é NH(C=W)R5 ou W é O ou S; R~ 2~ e R~ 3~ são, por exemplo, H ou F; R~ 1~ é, por exemplo, hidrogênio ou halogênio; R~ 5~ é selecionado de hidrogênio, (2-6C)alquila (opcionalmente substituída); R~ 6~ e R~ 7~ são independentemente selecionados de hidrogênio e (1-4C)alquila (opcionalmente substituída); em que R4 é um substituinte hidroximetila em C-4<39> do anel isoxazolina; ou R~ 4~ é um substituinte hidroximetila de C-5<39> do anel isoxazolina e a estereoquímica em C-5<39> do anel isoxazolina e em C-5 do anel oxazolidinona é selecionada, de modo que o composto de fórmula (I) é um único diastereómero; são úteis como agentes antibacterianos; e processos para sua manufatura e composições farmacêuticas contendo os mesmos.
BRPI0407835-7A 2003-03-01 2004-02-24 composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis BRPI0407835A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0304723A GB0304723D0 (en) 2003-03-01 2003-03-01 Chemical compounds
GB0318607A GB0318607D0 (en) 2003-08-08 2003-08-08 Chemical compounds
PCT/GB2004/000730 WO2004078753A1 (en) 2003-03-01 2004-02-24 Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents

Publications (1)

Publication Number Publication Date
BRPI0407835A true BRPI0407835A (pt) 2006-02-14

Family

ID=32964061

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407835-7A BRPI0407835A (pt) 2003-03-01 2004-02-24 composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis

Country Status (16)

Country Link
US (1) US7192974B2 (pt)
EP (1) EP1599471B1 (pt)
JP (1) JP2006519247A (pt)
KR (1) KR20050106064A (pt)
AT (1) ATE396991T1 (pt)
AU (1) AU2004218206A1 (pt)
BR (1) BRPI0407835A (pt)
CA (1) CA2517706A1 (pt)
CL (1) CL2004000400A1 (pt)
DE (1) DE602004014107D1 (pt)
ES (1) ES2305732T3 (pt)
MX (1) MXPA05009205A (pt)
NO (1) NO20054523L (pt)
TW (1) TW200500360A (pt)
UY (1) UY28211A1 (pt)
WO (1) WO2004078753A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304536T1 (de) * 2001-04-17 2005-09-15 Merck & Co Inc Bicyclo(3,1,0)hexan als strukturelement enthaltende oxazolidinon-antibiotika und deren derivate
CN1649866A (zh) 2002-02-28 2005-08-03 阿斯特拉曾尼卡有限公司 3－环状基－5－(含氮5－元环)甲基－噁唑烷酮衍生物及其作为抗菌药物的用途
CN1653064A (zh) 2002-02-28 2005-08-10 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及包含它们的药用组合物
EP1656370B1 (en) * 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
WO2005012271A2 (en) * 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
AU2004256086B2 (en) * 2003-07-02 2007-12-06 Kyorin Pharmaceutical Co., Ltd. Oxazolidinone antibiotics and derivatives thereof
CA2529292A1 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
ATE471937T1 (de) * 2003-07-02 2010-07-15 Merck Sharp & Dohme Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
US20070185132A1 (en) * 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
ES2536001T3 (es) * 2003-07-29 2015-05-19 Melinta Therapeutics, Inc. Procedimiento para la síntesis de biariloxazolidinonas
WO2005033079A1 (ja) * 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
AR046782A1 (es) 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
WO2005116024A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections
US20080064689A1 (en) * 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
GB0411596D0 (en) * 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
WO2006038100A1 (en) * 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
JP5534497B2 (ja) 2005-06-08 2014-07-02 メリンタ セラピューティクス，インコーポレイテッド トリアゾール類の合成方法
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
WO2007052479A1 (ja) * 2005-11-04 2007-05-10 Ngk Insulators, Ltd. ハニカム構造体及びハニカム触媒体
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
EP2065377B1 (en) * 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
US8258394B2 (en) * 2007-02-08 2012-09-04 Bradford G Baruh Retractable solar panel system
US20080190341A1 (en) * 2007-02-08 2008-08-14 Baruh Bradford G System and method of adjusting the location and position of the foresail on a sailboat
US20100065104A1 (en) * 2007-08-31 2010-03-18 Baruh Bradford G Retractable solar panel system
KR100848232B1 (ko) 2007-04-12 2008-07-24 일동제약주식회사 신규 헤테로 고리 또는 알콕시아미노메틸 옥사졸리디논 및그 제조방법
WO2008136279A1 (ja) * 2007-04-27 2008-11-13 Eisai R & D Management Co., Ltd. ヘテロ環置換ピリジン誘導体の塩またはその結晶
TW200841879A (en) * 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CA2726420C (en) * 2007-06-01 2018-07-31 Chx Technologies, Inc. Topical dental solution of chlorhexidine in sumatra benzoin bp/ep and methods of manufacturing and evaluating same for compliance with international regulatory specifications
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
RU2659792C1 (ru) 2008-10-10 2018-07-04 Мерк Шарп Энд Домэ Корп. Оксазолидиноны и способ их очистки
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
MY156354A (en) 2009-02-03 2016-02-15 Merck Sharp & Dohme Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
CN102348696B (zh) * 2009-03-13 2015-06-17 太阳化学有限公司 可用于可能量固化的组合物中的环状氨基甲酸酯化合物
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
KR101653570B1 (ko) * 2011-03-30 2016-09-02 주식회사 레고켐 바이오사이언스 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
EP2626356A1 (en) * 2012-02-08 2013-08-14 Rheinische Friedrich-Wilhelms-Universität Bonn Thiamine analogues and their use as antibiotics
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
CN112707779B (zh) * 2020-12-26 2023-06-30 蚌埠中实化学技术有限公司 一种乙烯基环己烷的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA &amp; UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
AU5889701A (en) * 2000-06-05 2001-12-17 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
SI1427711T1 (sl) * 2001-09-11 2005-12-31 Astrazeneca Ab Oksazolidinonski in/ali izoksazolinski derivati kot antibakterijska sredstva
MXPA05005651A (es) * 2002-11-28 2005-07-27 Astrazeneca Ab Derivados de oxazolidinona y/o isoxazolina como agentes antibacterianos.
GB0227701D0 (en) * 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
GB0229526D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CL2004000400A1 (es) 2005-04-22
DE602004014107D1 (de) 2008-07-10
AU2004218206A1 (en) 2004-09-16
EP1599471A1 (en) 2005-11-30
NO20054523D0 (no) 2005-09-30
CA2517706A1 (en) 2004-09-16
ES2305732T3 (es) 2008-11-01
TW200500360A (en) 2005-01-01
KR20050106064A (ko) 2005-11-08
EP1599471B1 (en) 2008-05-28
JP2006519247A (ja) 2006-08-24
UY28211A1 (es) 2004-09-30
MXPA05009205A (es) 2005-10-18
HK1083097A1 (en) 2006-06-23
NO20054523L (no) 2005-12-01
ATE396991T1 (de) 2008-06-15
US20060270637A1 (en) 2006-11-30
US7192974B2 (en) 2007-03-20
WO2004078753A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
BRPI0407835A (pt) composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis
RU2340618C2 (ru) Диазинопиримидины и фармацевтическая композиция, содержащая их
EA200501098A1 (ru) Антибактериальные агенты
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
BR0212458A (pt) Composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, composição farmacêutica, e, processo para a preparação de um composto ou sais farmaceuticamente aceitável, ou ésteres hidrolizáveis in vivo deste
NZ509321A (en) Use of an estrogen agonist/antagonist to treat conditions responsive to estrogen such as rheumatoid arthritis, colon cancer, tissue wounds and cataracts
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
ATE398627T1 (de) C-2-modifizierte erythromycinderivate
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
RU2450015C2 (ru) Производные аминотиазола и их применение в качестве антибактериальных средств
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
JO2413B1 (en) Benzoxazine derivatives and their use
PL432858A1 (pl) Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz sposób otrzymywania produktu pośredniego
UY27979A1 (es) Indoles sustituidos en posición 2,4
MXPA04008926A (es) Inhibidores de entrada a moleculas pequenas.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
PE20080283A1 (es) Profarmacos antimicrobianos de oxazolidinona
WO2003072576A3 (en) Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
WO2008038092A3 (en) Substituted piperidinophenyl oxazolidinones
JOP20210353A1 (ar) مركبات وطرق استخدامها كعوامل مضادة للجراثيم
AR064680A1 (es) Derivados de etilamino- fenilo heterociclico sustituidos, su preparacion y su uso como medicamentos
PH20392A (en) Pyridobenzodiazepinones pharmaceutical compositions thereof and method of use thereof
CA2531766A1 (en) Entry inhibitors of the hiv virus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.